Form 4: Milton C. Ault III Increases Stake in Alzamend Neuro, Inc.
SEC Form 4 Filing
Director Milton C. Ault III reports purchasing additional shares of Alzamend Neuro, Inc. through a direct purchase and entities he controls.
Summary
- On March 21, 2025, Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., acquired 2,905 shares of common stock at a price of $1.022 per share.
- The shares were purchased directly.
- Following the transaction, Ault directly owns 16,686 shares.
- Ault also indirectly owns 85,273 shares through Ault Lending, LLC, 99,619 shares through Ault Life Sciences, Inc., and 549 shares through Ault Life Sciences Fund, LLC.
Sentiment
Score: 6
Explanation: The sentiment is neutral. Insider buying can be seen as a positive signal, but without additional context, it's difficult to gauge the overall impact.
Positives
- The director's purchase could be interpreted as a positive signal about the company's prospects.
Industry Context
This filing is a routine disclosure required by the SEC for insiders who trade in their company's stock. It provides transparency to the market about the actions of key individuals.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/21/2025 | Date of transaction: Purchase of 2,905 shares of common stock. |
| 03/25/2025 | Date of signature for the Form 4 filing. |
Keywords
Alzamend Neuro, ALZN, Milton C. Ault III, Beneficial Ownership, Form 4, Insider Trading, Ault Lending, Ault Life Sciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.